ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.03, read 2026-10-28
Ethical passes the values gate
Price11.28 USD
Fair value19.13
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation9.51+18.6% to today ✓Markdown gives way to Accumulation after a 7% rise in 13 days
2026-09-19Read Markdown8.90+26.7% to today Accumulation gives way to Markdown
2026-07-20Read Accumulation8.71+29.5% to today ✓Distribution gives way to Accumulation after a 6% rise in 3 weeks
2026-07-02Read Distribution8.21+37.4% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
ADMA Biologics, Inc. holds its Accumulation at $11.28. The statistical read favours the sellers, held for 97 days.
As held on the ledger · 2026-10-28
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 97 days
Price at the screen
$11.28
Valuation
15.73 trailing · 11.67 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.69
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.80%
Below 33%
Interest-bearing debt is just 12.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
39.42%
Below 49%
Money owed to the company is 39.4% of assets, under the 49% limit.
Pass
Revenue purity
0.37%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
ADMA Biologics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 13%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ADMA's ethical verdict changes
Today ADMA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 69.6% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +55% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Plasma treatments for immune gaps at half price
When the body cannot fight infections on its own, plasma-derived antibodies become the difference between hospital stays and normal life. ADMA Biologics makes those treatments and has scaled output to meet rising demand. The shares sit at $8.71 against a fair value of $17.42, a margin that reflects real cash generation rather than hope.
Revenue is rising 16 percent, the firm converts one third of sales into profit, and it earns 43 percent on equity. Forward earnings sit at just 8.8 times while five analysts see the same path to roughly double the current price. The ethical screen raises no flags, which keeps the name on the list despite an unknown moat.
Biotech output can still swing with plasma supply, regulatory checks, and competition that is hard to forecast. Low multiples on cyclical or execution-heavy businesses often signal peak earnings rather than bargains. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ADMA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Accumulation$11.01+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$11.01+2.6%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-10-19Accumulation$10.73+3.6%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-10-12Accumulation$10.36+8.9%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-10-02Accumulation · changed$9.51+6.9%Entry 8
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-09-19Markdown · changed$8.90-9.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-08-20Accumulation$9.78+12.3%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-07-20Accumulation · changed$8.71+6.1%Entry 5
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-07-18Distribution$8.21+0.0%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
2026-07-16Distribution$8.21+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (4 analysts) rates it none, with a mean price target of $17.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
